Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diab…

Objective: German national treatment guidelines recommend HbA1c target range 6.5 – 7.5% for 'healthy' patients with T2D. Data from an open-label AWARD-4 subpopulation with baseline HbA1c ≥7.5% (above recommended target range) and ≤11% (˜80% intent-to-treat population) were analysed comparing dulaglutide vs. glargine, both with lispro ± metformin. Methods: Efficacy and safety data from eligible patients uncontrolled on conventional insulin regimens receiving once-weekly dulaglutide 1.5 mg (N = 228) or glargine (N = 239) were compared post-hoc at 26 weeks (primary endpoint). Results: In this subpopulation, (all le…